ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2239

Increased Cardiovascular Morbidity in Patients with Rheumatoid Arthritis and Type 2 Diabetes: A Large-Scale Electronic Health Record Analysis

Godbless Ajenaghughrure1, Sila Mateo Faxas2, Gurjot Singh3, Nirys Mateo Faxas4, Kim Nguyen3, Nicole Tejeda5 and Kimberly Ramirez Bonetti6, 1Trihealth Good Samaritan Hospital, Cincinnati, OH, 2Good Samaritan Hospital, Cincinnati, OH, 3Trihealth Good Samaritan Hospital, Cincinnati, 4Independent Author, Santo Domingo, Dominican Republic, 5Independent Author, Cincinnati, 6Independent Author, cincinnati, OH

Meeting: ACR Convergence 2025

Keywords: rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular risk, but the additional impact of comorbid type 2 diabetes mellitus (T2DM) on cardiovascular outcomes in this population remains incompletely characterized. This study evaluated the cardiovascular burden in patients with both RA and T2DM compared to patients with RA alone.

Methods: Using the TriNetX global federated health research network, we conducted a retrospective cohort study of 187,967 patients with RA from 100 healthcare organizations. Patients aged 18-99 years with RA (ICD-10 M06.9) were stratified by T2DM status (ICD-10 E11). After propensity score matching for cardiovascular risk factors and comorbidities, we analyzed 129,630 patients in each cohort. Cardiovascular outcomes were assessed over a 5-year follow-up period.

Results: Patients with comorbid RA and T2DM demonstrated significantly higher risk of mortality (HR 1.73, 95% CI 1.69-1.78, p < 0.001), cardiac arrest (HR 2.85, 95% CI 2.61-3.10, p < 0.001), and heart failure (HR 1.93, 95% CI 1.86-1.96, p < 0.001) compared to patients with RA alone. Additionally, the comorbid group showed increased risk of atrial fibrillation (HR 1.97, 95% CI 1.92-2.02, p < 0.001), ventricular arrhythmias (HR 2.18, 95% CI 2.05-2.32, p < 0.001), cerebral infarction (HR 1.67, 95% CI 1.60-1.75, p < 0.001), and acute kidney failure (HR 2.57, 95% CI 2.49-2.66, p < 0.001). Patients with both conditions also required more cardiac device implantations (HR 2.65, 95% CI 2.50-2.80, p < 0.001).

Conclusion: Coexisting T2DM in patients with RA substantially increases the risk of major adverse cardiovascular events and mortality. These findings highlight the need for aggressive cardiovascular risk assessment and management strategies in this high-risk population. Interdisciplinary care involving rheumatologists and endocrinologists may be crucial for optimal management of this patient group.


Disclosures: G. Ajenaghughrure: None; S. Mateo Faxas: None; G. Singh: None; N. Mateo Faxas: None; K. Nguyen: None; N. Tejeda: None; K. Ramirez Bonetti: None.

To cite this abstract in AMA style:

Ajenaghughrure G, Mateo Faxas S, Singh G, Mateo Faxas N, Nguyen K, Tejeda N, Ramirez Bonetti K. Increased Cardiovascular Morbidity in Patients with Rheumatoid Arthritis and Type 2 Diabetes: A Large-Scale Electronic Health Record Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/increased-cardiovascular-morbidity-in-patients-with-rheumatoid-arthritis-and-type-2-diabetes-a-large-scale-electronic-health-record-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-cardiovascular-morbidity-in-patients-with-rheumatoid-arthritis-and-type-2-diabetes-a-large-scale-electronic-health-record-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology